June 7, 2017

Amicus Therapeutics to Present at Goldman Sachs 38th Annual Global Healthcare Conference

May 31, 2017

Amicus Therapeutics Receives Rare Pediatric Disease Designation for SD-101 for Patients with Epidermolysis Bullosa

May 19, 2017

Amicus Therapeutics Announces Planned Analysis of Primary Endpoints in Phase 3 Epidermolysis Bullosa Study